REG - Avacta Group PLC - Block Listing Six Monthly Return

AvactaAnnouncement

27/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231027:nRSa4522Ra&default-theme=true

RNS Number : 4522R  Avacta Group PLC  27 October 2023

 

 

 

 

 

 

27 October 2023

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

 

Avacta Group plc (AIM: AVCT), a life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics, today
makes the following notification pursuant to Schedule Six of the AIM Rules for
Companies regarding its existing block admission arrangements:

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     EMI scheme
 Period of return:                         From:                                     28 April 2023          27 October 2023
 Balance of unallotted securities under scheme(s) from previous return:              414,178
 Plus:   The amount by which the block scheme(s) has been increased since            600,000
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 216,256
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         797,922

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     LTIP scheme
 Period of return:                         From:                                     28 April 2023          27 October 2023
 Balance of unallotted securities under scheme(s):                                   2,370,589
 Plus:   The amount by which the block scheme(s) has been increased since            3,700,000
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 793,332
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         5,277,257

 

 Name of contact:              Tony Gardiner, Company Secretary
 Telephone number of contact:  + 44 (0) 1904 217070

 

Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                          Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                   www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker)         Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / William   www.stifel.com (http://www.stifel.com/)
 Palmer-Brown

 Peel Hunt (Joint Corporate Broker)                                        Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                             www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                              avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

 

Avacta Group is a UK-based company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: an oncology biotech division harnessing proprietary
therapeutic platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, which is executing on an M&A led growth strategy to
create a full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two proprietary
platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst
the diagnostics division leverages the Affimer® platform to drive competitive
advantage in its markets.

 

The pre|CISION™ platform modifies chemotherapy to be activated only in the
tumour tissue, reducing systemic exposure and toxicity. This is achieved by
harnessing an enzyme called FAP which is highly upregulated in most solid
tumours compared with healthy tissues, turning chemotherapy into a "precision
medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form
of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in
safety compared with standard doxorubicin, and early signs of clinical
activity.

 

Affimer® is a novel biologic platform which has significant technical and
commercial advantages compared with antibodies and is used both to develop
advanced immunotherapies and to improve the performance of immunodiagnostics.

 

With a balanced business and capital allocation model: a high-value oncology
pipeline supported by a revenue generating, fast-growing diagnostics business,
Avacta seeks to create long-term shareholder value alongside patient benefit.

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRPPGQPUUPWGAQ